: Tempest Therapeutics shares head back to earth after 4,000% gain

Oncology company’s stock drops more than 50% as it seeks partners to help advance investigational cancer treatment.

Previous post Extra Credit: Federal regulator investigating whether student-loan servicer is collecting on debt discharged in bankruptcy
Next post Market Extra: Subprime car-loan rates are hitting 17%-22%. Should investors be worried?